RS49882B - Postupak kristalizacije derivata tetrahidropiridina i dobijeni kristalni oblici - Google Patents

Postupak kristalizacije derivata tetrahidropiridina i dobijeni kristalni oblici

Info

Publication number
RS49882B
RS49882B YUP-289/99A YU28999A RS49882B RS 49882 B RS49882 B RS 49882B YU 28999 A YU28999 A YU 28999A RS 49882 B RS49882 B RS 49882B
Authority
RS
Serbia
Prior art keywords
mixture
ethyl
naphth
trifluoromethylphenyl
iii
Prior art date
Application number
YUP-289/99A
Other languages
English (en)
Serbian (sr)
Inventor
Antoine CARON
Bruno FRANC
Olivier MONNIER
Original Assignee
Sanofi-Aventis,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis, filed Critical Sanofi-Aventis,
Publication of YU28999A publication Critical patent/YU28999A/sh
Publication of RS49882B publication Critical patent/RS49882B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
YUP-289/99A 1996-12-23 1997-12-23 Postupak kristalizacije derivata tetrahidropiridina i dobijeni kristalni oblici RS49882B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9615904A FR2757543B1 (fr) 1996-12-23 1996-12-23 Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues

Publications (2)

Publication Number Publication Date
YU28999A YU28999A (sh) 2003-01-31
RS49882B true RS49882B (sr) 2008-08-07

Family

ID=9499043

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-289/99A RS49882B (sr) 1996-12-23 1997-12-23 Postupak kristalizacije derivata tetrahidropiridina i dobijeni kristalni oblici

Country Status (38)

Country Link
EP (1) EP0950050B1 (en:Method)
JP (2) JP4499188B2 (en:Method)
KR (1) KR100586670B1 (en:Method)
CN (1) CN1129580C (en:Method)
AR (1) AR009672A1 (en:Method)
AT (1) ATE307802T1 (en:Method)
AU (1) AU736697B2 (en:Method)
BR (1) BR9714081A (en:Method)
CA (1) CA2275596C (en:Method)
CO (1) CO5070688A1 (en:Method)
CZ (1) CZ296689B6 (en:Method)
DE (1) DE69734460T2 (en:Method)
DK (1) DK0950050T3 (en:Method)
DZ (1) DZ2383A1 (en:Method)
EE (1) EE04188B1 (en:Method)
EG (1) EG21567A (en:Method)
ES (1) ES2251038T3 (en:Method)
FR (1) FR2757543B1 (en:Method)
HR (1) HRP970699B1 (en:Method)
HU (1) HU227425B1 (en:Method)
IL (1) IL129938A (en:Method)
IN (1) IN186976B (en:Method)
IS (1) IS2357B (en:Method)
MY (1) MY118015A (en:Method)
NO (1) NO312364B1 (en:Method)
NZ (1) NZ336130A (en:Method)
PL (1) PL190494B1 (en:Method)
RS (1) RS49882B (en:Method)
RU (1) RU2192416C2 (en:Method)
SA (1) SA98180971B1 (en:Method)
SI (1) SI0950050T1 (en:Method)
SK (1) SK285088B6 (en:Method)
TR (1) TR199901363T2 (en:Method)
TW (1) TW518322B (en:Method)
UA (1) UA60324C2 (en:Method)
UY (1) UY24825A1 (en:Method)
WO (1) WO1998028271A1 (en:Method)
ZA (1) ZA9711576B (en:Method)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2757543B1 (fr) * 1996-12-23 1999-04-02 Sanofi Sa Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues
FR2782082B3 (fr) * 1998-08-05 2000-09-22 Sanofi Sa Formes cristallines de (r)-(+)-n-[[3-[1-benzoyl-3-(3,4- dichlorophenyl)piperidin-3-yl]prop-1-yl]-4-phenylpiperidin-4 -yl]-n-methylacetamide (osanetant) et procede pour la preparation dudit compose
US9272068B2 (en) 2010-03-12 2016-03-01 Nippon Shokubai Co., Ltd. Process for producing water-absorbing resin
ES2604405T3 (es) * 2011-04-15 2017-03-06 Emcure Pharmaceuticals Limited Un procedimiento para rilpivirina mejorado

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2531707A1 (fr) * 1982-08-16 1984-02-17 Midy Spa Trifluoromethylphenyltetrahydropyridines substituees a activite anorexigene, un procede de preparation et compositions pharmaceutiques
FR2757543B1 (fr) * 1996-12-23 1999-04-02 Sanofi Sa Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues

Also Published As

Publication number Publication date
ATE307802T1 (de) 2005-11-15
FR2757543B1 (fr) 1999-04-02
BR9714081A (pt) 2000-05-09
EE9900264A (et) 2000-02-15
AU5668498A (en) 1998-07-17
EG21567A (en) 2001-12-31
WO1998028271A1 (fr) 1998-07-02
IN186976B (en:Method) 2001-12-22
EP0950050B1 (fr) 2005-10-26
CZ296689B6 (cs) 2006-05-17
NO993076L (no) 1999-06-22
SA98180971B1 (ar) 2006-09-13
DZ2383A1 (fr) 2002-12-28
ES2251038T3 (es) 2006-04-16
IS2357B (is) 2008-04-15
NO993076D0 (no) 1999-06-22
CZ229299A3 (cs) 1999-09-15
PL334256A1 (en) 2000-02-14
PL190494B1 (pl) 2005-12-30
CA2275596C (en) 2005-10-11
HUP0001387A2 (hu) 2000-09-28
TR199901363T2 (xx) 1999-08-23
IS5076A (is) 1999-06-10
AR009672A1 (es) 2000-04-26
SK285088B6 (sk) 2006-06-01
RU2192416C2 (ru) 2002-11-10
SK82899A3 (en) 1999-12-10
KR100586670B1 (ko) 2006-06-07
CN1129580C (zh) 2003-12-03
DE69734460T2 (de) 2006-07-06
NZ336130A (en) 2001-01-26
IL129938A (en) 2004-06-20
HRP970699A2 (en) 1998-10-31
IL129938A0 (en) 2000-02-29
DK0950050T3 (da) 2006-01-23
FR2757543A1 (fr) 1998-06-26
EP0950050A1 (fr) 1999-10-20
HRP970699B1 (en) 2007-03-31
AU736697B2 (en) 2001-08-02
KR20000069504A (ko) 2000-11-25
JP4499188B2 (ja) 2010-07-07
CO5070688A1 (es) 2001-08-28
EE04188B1 (et) 2003-12-15
HUP0001387A3 (en) 2002-03-28
MY118015A (en) 2004-08-30
HK1024002A1 (en) 2000-09-29
JP2009197022A (ja) 2009-09-03
CN1241180A (zh) 2000-01-12
TW518322B (en) 2003-01-21
YU28999A (sh) 2003-01-31
UA60324C2 (uk) 2003-10-15
SI0950050T1 (sl) 2006-04-30
JP2001507012A (ja) 2001-05-29
NO312364B1 (no) 2002-04-29
CA2275596A1 (en) 1998-07-02
HU227425B1 (en) 2011-05-30
ZA9711576B (en) 1998-06-25
DE69734460D1 (de) 2005-12-01
UY24825A1 (es) 1998-04-21

Similar Documents

Publication Publication Date Title
TW201213325A (en) Crystalline forms of pyrimidio [6,1-A] isoquinolin-4-one compounds
MXPA04010468A (es) Metodo par la produccion de cristales, cristales obtenidos por dicho metodo y uso de los mismos en formulaciones farmaceuticas.
CA2353693C (en) Pharmaceutical composition containing citalopram
WO2011069608A1 (en) S-lenalidomide, polymorphic forms thereof and blend comprising s- und r-lenalidomide
CA3157883C (en) A composition comprising levamlodipine besylate hydrate and its preparation method
US20080261959A1 (en) Novel crystalline forms of (S)-N-(1-Carboxy-2-methyl-prop-1-y)-N-pentanoyl-N[2'-(1H-tetrazol-5-yl)bi-phenyl-4-ylmethyl]-amine
RS49882B (sr) Postupak kristalizacije derivata tetrahidropiridina i dobijeni kristalni oblici
MXPA04010467A (es) Metodo para la produccion de cristales de esteroides, cristales obtenidos mediante dicho metodo, y su uso en formulaciones farmaceuticas.
US6489334B2 (en) Method for the crystallization of a tetrahydropyridin derivative and resulting crystalline forms
TW534820B (en) Microparticulate form of a tetrahydropyridine derivative and a pharmaceutical composition containing the same
MXPA06006731A (es) Forma polimorfica de dexcetoprofeno trometamol, su preparacion y composiciones que lo contienen.
US20020193386A1 (en) Polymorphic form of 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-alpha]pyrimidin-4-one and formulations thereof
TWI378929B (en) Crystalline 1h-imidazo[4,5-b]pyridin-5-amine, 7-[5-[(cyclohexylmethylamino)-methyl]-1h-indol-2-yl]-2-methyl, sulfate (1:1), trihydrate and its pharmaceutical uses
MXPA99005620A (en) Method for the crystallisation of a tetrahydopyridin derivative and resulting crystalline forms
US20030191140A1 (en) Polymorphic form of 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-alpha]pyrimidin-4-one and formulations thereof
HRP970701A2 (en) Micro-particulate form of a tetrahydropyridin derivative
MXPA99005621A (en) Micro-particulate form of a tetrahydropyridin derivative
CN110384673A (zh) 右旋奥拉西坦胶囊及其制备方法
JPS5916820A (ja) 無晶形マロチラ−トを含有する固形製剤組成物